Skip to Content

Covenant Asset Management LLC buys 7,408 United Therapeutics Co. shares (NASDAQ:UTHR)

Covenant Asset Management LLC buys 7,408 United Therapeutics Co. shares (NASDAQ:UTHR)

According to the most recent Form 13F filing that Covenant Asset Management LLC submitted to the Securities and Exchange Commission, the company increased its holdings in United Therapeutics Company (NASDAQ: UTHR) by 107.5% during the third quarter. The biotechnology company’s stock increased by 7,408 new shares during the quarter, bringing the total number of ownership shares in the business to 14,298. United Therapeutics is the 23rd largest company in the portfolio, which Covenant Asset Management LLC manages. This is because the company holds a share value of 0.9%. The most recent report that the Securities and Exchange Commission received revealed that the holdings of Covenant Asset Management LLC in United Therapeutics were valued at $2,994,000. The report was filed with the Securities and Exchange Commission by the Securities and Exchange Commission.

Several other hedge funds have recently implemented various changes to the proportion of the company’s shares that they own. In the second quarter, Calamos Advisors LLC incurred expenses totaling approximately 525,000 dollars to purchase a new investment in United Therapeutics. UMB Bank, National Association increased the amount of United Therapeutics stock owned by 91.8% during the second quarter of the fiscal year. Following the acquisition of an additional 625 shares during the period in question, UMB Bank n.a. now holds 1,306 shares of the stock held by the biotechnology company. These shares are currently estimated to be in the neighborhood of $308,000. Hallmark Capital Management Inc. invested approximately $33,000 during the second quarter to increase its holdings in United Therapeutics and its stake in the company. Following the purchase of an additional interest in the business during the second quarter, Roman Butler Fullerton & Co. purchased a new stake in United Therapeutics for approximately $1,573,000 to increase its ownership in the company.

Last but not least, during the second quarter, TriaGen Wealth Management LLC spent approximately $320,000 to purchase a new position in United Therapeutics. This is certainly not the most important investment. The vast majority of the company’s stock is owned by institutional investors and hedge funds, which account for 95.63 percent of the total.

Recent times have seen several stock research analysts produce studies on the company, which they have compiled and analyzed individually. The Goldman Sachs Group published a research report for the first time on Monday, December 5, marking the first day that United Therapeutics was included in the report. They suggested a “sell” price of $230.00 for the stock, which was also the level at which they set their target price. In a research note published by HC Wainwright on November 3, the first day that United Therapeutics was included in a research report issued by the Goldman Sachs Group, the company was given a “buy” rating with a price target of $300.00. This was also the first time United Therapeutics was included in a research report. They suggested a “sell” price of $230.00 for the stock, which was also the level at which they set their target price. In a research note distributed by HC Wainwright on November 3, the company assigned a “buy” rating to United Therapeutics and set a price target of $300 for the stock. The report suggested a price target of $300.00 for United Therapeutics, which was an increase from the previous price target of $255.00. Morgan Stanley increased its price target for United Therapeutics from $322.00 to $33

Tags

Leave a comment

Your email address will not be published. Required fields are marked *